These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 7936284)

  • 1. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
    Vidailhet M; Bonnet AM; Marconi R; Gouider-Khouja N; Agid Y
    Neurology; 1994 Sep; 44(9):1613-6. PubMed ID: 7936284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyskinesias and the subthalamic nucleus.
    Benabid AL; Benazzouz A; Limousin P; Koudsie A; Krack P; Piallat B; Pollak P
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
    Cubo E; Gracies JM; Benabou R; Olanow CW; Raman R; Leurgans S; Goetz CG
    Arch Neurol; 2001 Sep; 58(9):1379-82. PubMed ID: 11559308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
    Kostić VS; Marinković J; Svetel M; Stefanova E; Przedborski S
    Eur J Neurol; 2002 Jan; 9(1):9-14. PubMed ID: 11784369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS; Andrade LA; Ferraz HB; Borges V
    Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease.
    Guerra A; Suppa A; D'Onofrio V; Di Stasio F; Asci F; Fabbrini G; Berardelli A
    Brain Stimul; 2019; 12(6):1517-1525. PubMed ID: 31217080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms.
    Pietracupa S; Fasano A; Fabbrini G; Sarchioto M; Bloise M; Latorre A; Altieri M; Bologna M; Berardelli A
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1004-8. PubMed ID: 23890762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease.
    Krack P; Pollak P; Limousin P; Hoffmann D; Xie J; Benazzouz A; Benabid AL
    Brain; 1998 Mar; 121 ( Pt 3)():451-7. PubMed ID: 9549521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of two iatrogenic dyskinesias.
    Karson CN; Jeste DV; LeWitt PA; Wyatt RJ
    Am J Psychiatry; 1983 Nov; 140(11):1504-6. PubMed ID: 6137963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor complications of chronic levodopa therapy in Parkinson's disease.
    Miyawaki E; Lyons K; Pahwa R; Tröster AI; Hubble J; Smith D; Busenbark K; McGuire D; Michalek D; Koller WC
    Clin Neuropharmacol; 1997 Dec; 20(6):523-30. PubMed ID: 9403226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
    Krack P; Pollak P; Limousin P; Benazzouz A; Deuschl G; Benabid AL
    Brain; 1999 Jun; 122 ( Pt 6)():1133-46. PubMed ID: 10356065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
    Schneider JS; Gonczi H; Decamp E
    Brain Res; 2003 Nov; 990(1-2):38-44. PubMed ID: 14568327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.